SK Bioscience, GSK Initiate Phase 3 Trial Of COVID-19 Vaccine Candidate
31/8 08:28
(RTTNews) - SK bioscience and GlaxoSmithKline plc (GSK.L, GSK) said Tuesday that they have initiated a phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination with GSK's pandemic adjuvant following positive interim phase 1/2 results....